FDA Subpoena Attorney: What to Do If FDA Agents or Federal Investigators Contact You
When most people think about FDA, they think about inspectors, forms, and warning letters. But some FDA matters do not stay administrative. They move into the hands of criminal investigators.
If you have received a subpoena connected to an FDA matter, if federal agents have contacted employees, or if the FDA Office of Criminal Investigations appears to be involved, the situation should be treated as a potential criminal case from the outset.
What is FDA-OCI?
FDA-OCI is the agency’s criminal-investigations arm. Unlike standard regulatory personnel, OCI special agents investigate suspected criminal violations involving FDA-regulated products and often work with DOJ prosecutors and other federal agencies.
That distinction matters. When OCI enters the picture, the government is no longer merely evaluating compliance. It may be testing intent, knowledge, concealment, false statements, interstate distribution, patient harm, promotional conduct, records integrity, or conspiracy.
What kinds of subpoenas appear in FDA-related investigations?
The document may not literally come from “FDA.” In many cases, it comes through a grand jury, DOJ, or another federal process tied to an FDA-backed investigation. The subject matter, however, may still be distinctly FDA-driven.
Common triggers include:
- adulteration or misbranding allegations,
- illegal marketing claims,
- unapproved drugs or biologics,
- compounded products sold outside lawful boundaries,
- falsified records or data-integrity problems,
- imports and counterfeit products,
- controlled-substance overlap,
- billing and fraud theories layered onto product allegations.
The key mistake is assuming the subpoena is just about company records. It may be about building a case against individuals.
What to do immediately after receiving an FDA-related subpoena
1. Preserve everything
Do not delete emails, texts, quality records, promotional files, drafts, databases, instant messages, or website materials. Preservation should happen immediately.
2. Centralize communications
Employees should not respond individually to investigators, counterparties, or reporters without direction.
3. Get counsel involved before producing documents
Production strategy matters. Scope, privilege, custodians, timing, sequencing, and the framing of your cover communications all matter.
4. Assess individual risk
Sometimes the company and key executives align. Sometimes they do not. Conflict analysis should happen early.
5. Investigate under privilege
You need to know the facts before the government decides them for you.
Why these matters are so dangerous
A company may think it is dealing with labeling, manufacturing, or online-marketing problems. Prosecutors may see a different story: notice, concealment, repeated conduct, financial gain, or reckless disregard.
That gap between how the company sees the issue and how the government frames it is often where cases are won or lost.
The moment a subpoena arrives, every decision starts creating a defense record:
- who was told,
- what was preserved,
- whether facts were investigated,
- whether witnesses were prepared,
- whether the company corrected or continued,
- whether management appeared credible.
Parallel proceedings are common
FDA criminal matters rarely live alone. A company may face some combination of:
- FDA inspectional activity,
- warning letters,
- recalls,
- import action,
- payer scrutiny,
- state-board issues,
- qui tam or civil-fraud exposure,
- product-liability exposure,
- reputational damage.
A defense plan that ignores the parallel fronts is incomplete.
Why Ronald W. Chapman II is especially well suited for FDA-OCI and subpoena matters
This is where Ronald W. Chapman II’s background matters most.
He is a former federal prosecutor and U.S. Marine Corps Judge Advocate who now defends professionals and organizations in high-stakes federal matters. He holds an LL.M. in Health Care Law and has substantial experience at the intersection of healthcare regulation, fraud investigations, and federal enforcement. His record includes major healthcare fraud victories and defense work for regulated entities facing complex government scrutiny.
That combination is powerful in FDA-related subpoena matters because these cases often sit at the overlap of science, records, billing, marketing, and criminal intent. They require someone who can talk to prosecutors, understand the regulatory frame, and try the case if negotiations fail.
At Chapman, Dowling & Mallek, subpoena defense means more than document collection. It means investigating under privilege, identifying weaknesses in the government’s theory, protecting individual and corporate interests, preparing witnesses, managing exposure across agencies, and positioning the matter for resolution—or trial.
FAQ
Does a subpoena mean I will be charged?
No. But it does mean the government is gathering evidence in a serious way.
Should employees speak with agents?
They need legal guidance first. Even truthful conversations can be damaging if they are incomplete, imprecise, or poorly framed.
Can an FDA case become a healthcare fraud case?
Yes. In some matters, FDA theories and healthcare fraud theories overlap, especially when the conduct involves providers, prescriptions, claims, or reimbursements.
Call to action: If federal agents or prosecutors have contacted your business in connection with an FDA matter, act before the government finishes writing your version of the facts for you.